Heparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin-Free Medium, Enabling Consistent Manufacture of Cardiomyocytes

Author:

Lin Yongshun1,Linask Kaari L.1,Mallon Barbara2,Johnson Kory3,Klein Michael4,Beers Jeanette1,Xie Wen1,Du Yubin1,Liu Chengyu1,Lai Yinzhi5,Zou Jizhong16,Haigney Mark4,Yang Hushan5,Rao Mahendra6,Chen Guokai17

Affiliation:

1. a National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland, USA

2. b NIH Stem Cell Unit, NIH, Bethesda, Maryland, USA

3. c National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA

4. d Uniformed Services University of Health Sciences, Bethesda, Maryland, USA

5. e Thomas Jefferson University, Philadelphia, Pennsylvania, USA

6. f Center for Regenerative Medicine, NIH, Bethesda, Maryland, USA

7. g Faculty of Health Sciences, University of Macau, Tapai, Macau, People's Republic of China

Abstract

Abstract Cardiomyocytes can be differentiated from human pluripotent stem cells (hPSCs) in defined conditions, but efficient and consistent cardiomyocyte differentiation often requires expensive reagents such as B27 supplement or recombinant albumin. Using a chemically defined albumin-free (E8 basal) medium, we identified heparin as a novel factor that significantly promotes cardiomyocyte differentiation efficiency, and developed an efficient method to differentiate hPSCs into cardiomyocytes. The treatment with heparin helped cardiomyocyte differentiation consistently reach at least 80% purity (up to 95%) from more than 10 different hPSC lines in chemically defined Dulbecco's modified Eagle's medium/F-12-based medium on either Matrigel or defined matrices like vitronectin and Synthemax. One of heparin's main functions was to act as a Wnt modulator that helped promote robust and consistent cardiomyocyte production. Our study provides an efficient, reliable, and cost-effective method for cardiomyocyte derivation from hPSCs that can be used for potential large-scale drug screening, disease modeling, and future cellular therapies.

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3